Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2011 June;146(3) > Giornale Italiano di Dermatologia e Venereologia 2011 June;146(3):185-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Giornale Italiano di Dermatologia e Venereologia 2011 June;146(3):185-9

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Double blind clinical trial in a series of 115 patients with seborrheic dermatitis: prevention of relapses using a topical modulator of Toll Like Receptor 2

Ionescu M. A. 1, Baroni A. 2, Brambilla L. 3, Cannavò S. P. 4, Cristaudo A. 5, Dalle Vedove C. 6, Frasca M. 5, Girolomoni G. 6, Gnecchi L. 7, Peris K. 8, Trifirò C. 4, Matta A. M. 9, Robert G. 9

1 Dermatology Polyclinic, Saint-Louis Hospital, Paris, France; 2 Unit of Dermatology, University of Naples, Naples, Italy; 3 Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy; 4 Dermatological Clinic, University of Messina, Messina, Italy; 5 San Gallicano Dermatological Clinic, Rome, Italy; 6 Dermatological Clinic, University of Verona, Verona, Italy; 7 S. Gerardo University Hospital, Monza, Italy; 8 Dermatological Clinic, University of L’Aquila, L’Aquila, Italy; 9 Laboratoires Dermatologiques d’Uriage Courbevoie, France


PDF


AIM: Seborrheic dermatitis is a chronic inflammatory disease aggravated by Malassezia species. Toll-like receptors (TLR) are part of innate immune system that can be activated by yeasts. Previous studies showed that an association of Ombelliferae extract with a lipid (TLR2-RegulTM) decreases the IL-8 expression in human skin in contact with M. furfur. The aim of this study was to assess the activity of a topical formulated with TLR2-RegulTM in the prevention of seborrheic dermatitis (SD) relapses.
METHODS: Immune-competent SD adult patients were treated for SD (topical imidazoles or steroids). Cleared patients were randomized and received a topical containing TLR2-RegulTM (A) or its vehicle (B). Erythema, scales and pruritus were assessed during two months.
RESULTS: The study included 115 patients, mean age 43.4, sex ratio m/f 1.5. At week 4 the relapse rate was 26% (N.=15) in group A and 43% (N.=25) in group B. At W8 the relapse rate was 21% (N.=12) in group A and 40% (N.=23) (P=0.0309).
CONCLUSION: In this series of 115 adults with seborrheic dermatitis, patients treated with a topical containing TLR-RegulTM showed a significantly less relapse rate compared with the excipient group (P<0.05). TLR modulation could represent a new therapeutic approach in the prevention of seborrheic dermatitis relapses.

top of page